Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Invokana is a prescription sodium-glucose cotransporter 2 inhibitor containing canagliflozin. It improves glycemic control in adults and children age 10 and older with type 2 diabetes. Adult indications also include reduction of selected cardiovascular and kidney outcomes in patients who meet labeled criteria.
read more about invokana ...Canagliflozin inhibits sodium-glucose cotransporter 2 in the proximal renal tubules. This reduces reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion.
Invokana is used with diet and exercise for type 2 diabetes in adults and pediatric patients age 10 and older. In adults, it also reduces major adverse cardiovascular events in type 2 diabetes with established cardiovascular disease and reduces selected kidney and cardiovascular outcomes in diabetic nephropathy with albuminuria above 300 mg per day.
For glycemic control, treatment starts at 100 mg once daily before the first meal of the day. The dose can increase to 300 mg once daily when further glucose reduction is needed and kidney function meets current labeling criteria. For the labeled adult cardiovascular and kidney indications, the recommended dose is 100 mg once daily.
Serious concerns include ketoacidosis, lower limb amputation, volume depletion, acute kidney injury, urosepsis, pyelonephritis, Fournier gangrene, genital fungal infections, low blood glucose when combined with insulin or insulin secretagogues, and bone fracture. Kidney function and volume status are assessed before treatment.
Invokana improves glycemic control in children age 10 and older with type 2 diabetes.
The recommended starting dose is 100 mg once daily before the first meal of the day.
Yes. Current labeling permits 300 mg once daily for additional glycemic control when kidney function meets the dosing criteria.
No. Current labeling does not recommend Invokana for glycemic control in type 1 diabetes due to ketoacidosis risk.
Canagliflozin. https://www.ncbi.nlm.nih.gov/books/NBK603733/. Date Accessed October 5, 2026.
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. https://pubmed.ncbi.nlm.nih.gov/31291786/. Date Accessed October 5, 2026.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. https://pubmed.ncbi.nlm.nih.gov/30990260/. Date Accessed October 5, 2026.
Canagliflozin: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a613033.html. Date Accessed October 5, 2026.
INVOKANA (Canagliflozin) Prescribing Information. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9057d3b-b104-4f09-8a61-c61ef9d4a3f3. Date Accessed October 5, 2026.